Rapid responses to the COVID-19 through science and global collaboration: the solidarity clinical trial
Keywords:COVID-19, SARS-CoV-2, Clinical Trials, Hydroxychloroquine, Remdesivir
AbstractCOVID-19 represents a global crisis. Rapidly conducting a clinical trial with the rigor necessary to obtain reliable results requires the collaboration of various participants involved in the development, evaluation and authorization of clinical trials (CT) such as the trial sponsor, researchers, regulatory authority and the ethics committee (EC). Carrying out these studies is not only scientifically appropriate, but an ethical and moral obligation to guarantee our patients effective treatment. SOLIDARITY is a mega clinical trial that recruited thousands of subjects with moderate to severe disease, who were randomly assigned to one of the treatment groups under evaluation, including hydroxychloroquine, lopinavir/ritonavir associated or not with interferon; or remdesivir compared to standard therapy. Peru has joined the list of countries where the trial will be reproduced, through which it will be possible to quickly identify if any of these drugs offers a real benefit to patients
Download data is not yet available.
How to Cite
Soto A, Quiñones-Laveriano DM, García PJ, Gotuzzo E, Henao-Restrepo AM. Rapid responses to the COVID-19 through science and global collaboration: the solidarity clinical trial. Rev Peru Med Exp Salud Publica [nternet]. 2020 May 18 [cited 2023 Jun. 7];37(2):356-60. vailable from: https://rpmesp.ins.gob.pe/index.php/rpmesp/article/view/5546
Copyright (c) 2020 Revista Peruana de Medicina Experimental y Salud Pública
This work is licensed under a Creative Commons Attribution 4.0 International License.